FectoCHO® expression system is optimized for culture and transient protein expression of all CHO cells.
Meet our team booth #6 during the A3P Bioproduction meeting in Geneva (Switzerland), February 5th, 2019.
Our solutions for both protein and virus production
FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).
FectoCHO™ Expression System is a 3 component kit optimized to work together that contains FectoCHO™ CD Medium, FectoPRO® Transfection Reagent and FectoPRO® Expression Booster. FectoCHO™ Expression System has been developed to reach the highest protein production ever seen in CHO cell lines.
PEIpro® is a DNA transfection reagent for production of viruses, recombinant proteins and antibodies either in adherent cells in presence of serum or in suspension HEK-293 cells grown in low serum or serum-free media.
PEIpro® is a highly qualified grade of PEIpro® reagent, especially developed for the production of clinical batches of viral vectors or recombinant proteins and antibodies. The PEIpro®-HQ grade is supplied with appropriate Quality Controls and documentation allowing its use as a qualified raw material in GMP processes for the manufacturing of clinical batches of therapeutic products.
PEIpro®-GMP (NEW) is the highest quality grade PEI and the only transfection reagent available on the market supplied in a bag, ideal for GMP-compliant closed system manufacturing of clinical grade therapeutic viral vector.
General information about A3P Bioproduction meeting
The convention will take place at Intercontinental Hotel Geneva:
Chemin du Petit-Saconnex 7-9, 1209 Genève, Suisse
Join us on the social network
We created a dedicated event on Facebook to allow you to discuss with other scientists about the A3P meeting or about your transfection experiments.
If you want to talk about this event (Facebook, Twitter, Google+, etc…), don’t forget to use the #A3P19 and follow the A3P news.